November 2026
- CHF 150,000
- CHF 40,000
- 201 TherapeuticsCHF 150,000
201 Therapeutics, which stems from the University of Basel, is researching liver cancer drugs using organoids derived from patient tumours.
October 2026
- DecodeNAtureCHF 10,000
DecodeNAture rapidly identifies DNA in the field for agriculture, biosecurity and biodiversity monitoring.
- Topadur PharmaAmount not disclosed
Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a.
- Biodelphis TherapeuticsCHF 100,000
Biodelphis Therapeutics, an EPFL spin-off, couples a small molecule with an antibody to treat osteoporosis without acting on the whole body.
- Atlas BioUSD 10 M
Atlas Bio uses AI to simulate clinical trials and drug behaviour, in order to replace part of phase II trials and animal testing.
- Juturna BioCHF 50,000
Juturna Bio, an EPFL spin-off based at the Campus Biotech, is developing epigenetic therapies to restore the function of ageing brain cells, with Alzheimer's as the first target.
- NouscomUSD 135 M
Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome.
September 2026
- Prevision MedicineUSD 5.4 M
Prevision Medicine tests living tumour cells from patients against a large library of treatments to guide therapy choice in oncology.
- Ferm LabsEUR 3 M
Ferm Labs uses precision fermentation to produce natural, salt-free flavour enhancers from co-products.
- DataHowAmount not disclosed
DataHow provides AI and digital twin solutions for the development and production of pharmaceutical bioprocesses.
- NovaGo TherapeuticsCHF 24 M
NovaGo Therapeutics is developing anti-Nogo-A antibodies aimed at a first regenerative treatment for acute spinal cord injuries.
August 2026
- Adaptyv BiosystemsUSD 40 M
Adaptyv Biosystems runs an automated laboratory that rapidly validates AI-designed proteins experimentally.
- Vaderis TherapeuticsUSD 152 M
Vaderis Therapeutics develops targeted therapies for rare vascular diseases, including engasertib for hereditary haemorrhagic telangiectasia.
July 2026
- Immitra BioCHF 2.4 M
Immitra Bio is developing an in vivo gene-editing platform that does not depend on the mutation, with a lead candidate against an inherited anaemia.
June 2026
- Isospec AnalyticsCHF 400,000
Isospec Analytics, an EPFL spin-off, rapidly identifies biological molecules in patient samples for medical research.
- ClearideBio TherapeuticsAmount not disclosed
ClearideBio Therapeutics, founded in December 2025, develops antibody-drug conjugates against solid tumours.
- AlveoliXAmount not disclosed
AlveoliX develops organ-on-chip platforms that mimic human organs in vitro.
- CombioxinCHF 1.1 M
Combioxin is developing a drug for acquired immune deficiency in intensive care patients.
- TheraPPIAmount not disclosed
TheraPPI develops drugs that modulate protein interactions, with an oncology programme targeting ERK/MyD88 in the Ras-MAPK pathway.
May 2026
- NUCLIDIUMCHF 26 M
NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment.
- Windward BioUSD 165 M
Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma.
- BioCopyCHF 9 M
BioCopy develops TCR-mimetic bispecific antibodies against cancer, with an R&D site in Emmendingen, Germany.
April 2026
- Allegria TherapeuticsAmount not disclosed
Allegria Therapeutics develops mast cell-targeting therapies for allergic and inflammatory diseases.
- ALP BioCHF 1.8 M
ALP Bio combines human immune organoids with generative AI to reduce the immunogenicity risk of therapeutic antibodies.
- MabylonAmount not disclosed
Mabylon develops monoclonal antibodies, including MY012, which targets the inflammasome pathway.
- FERROSAUSD 3.5 M
FERROSA, founded in Basel in 2026 by Forty51 Ventures, is developing a bispecific antibody against inflammatory anaemia.
- CosaicUSD 6 M
Cosaic develops multifunctional food ingredients derived from yeast fermentation.
- PlanetaryCHF 16 M
Planetary is developing an integrated fermentation platform and licensing a technology that turns sugar by-products into protein.
March 2026
- NanoZymeXCHF 150,000
A University of Basel spin-off, NanoZymeX is developing a lipid nanoparticle platform to improve enzyme replacement therapies.
- Umlaut.bioEUR 3 M
Umlaut.bio is developing small molecules that target transfer RNA modifications for cancer and inflammatory diseases.
- EVis BioscienceEUR 740,000
ETH Zurich spin-off EVis Bioscience is developing an RNA delivery platform based on extracellular vesicles.
- Alithea GenomicsCHF 6.9 M
Alithea Genomics develops sample-preparation kits for large-scale RNA sequencing (BRB-seq, DRUG-seq).
January 2026
- FluoSpheraCHF 1.2 M
FluoSphera has developed an in vitro platform that combines up to seven human tissue models in a single well to predict drug efficacy and toxicity.
- TECregenCHF 10 M
Founded in 2023, TECregen develops biologics aimed at regenerating the thymus to restore immune function.
December 2025
- FoRx TherapeuticsUSD 50 M
FoRx Therapeutics develops FORX-428, an oral PARG enzyme inhibitor for advanced solid tumours, now in Phase 1 trials.
- Lemna BioCHF 100,000
Lemna Bio develops AI models that decode molecular interactions to identify therapeutic targets and drug candidates.
- VectopiaCHF 50,000
Vectopia, a University of Geneva spin-off, develops a new production method for lentiviral vectors used in gene therapy.
- ALLEGRIA TherapeuticsUSD 5.1 M
Founded in 2023, ALLEGRIA Therapeutics develops therapies targeting mast cells to treat allergies and associated inflammatory diseases.
- Aukera TherapeuticsAmount not disclosed
A University of Basel spin-off, Aukera Therapeutics develops selective mTORC1 (RAPTOR) inhibitors, initially for tuberous sclerosis complex.
November 2025
- VirometixUSD 15 M
Virometix develops fully synthetic vaccines against infectious diseases and cancer, including the anti-pneumococcal candidate V-212, now in Phase I.
- arcoris bioCHF 6.3 M
arcoris bio is developing MUSE, a nanotechnology platform for multiplexed biomarker detection in research and diagnostics.
- Calico BiosystemsAmount not disclosed
Calico Biosystems is a Swiss start-up developing cancer drugs.
- Precise HealthAmount not disclosed
Precise Health develops personalised bacteriophage technology to replace broad-spectrum antibiotics.
- SwitchkineCHF 250,000
Switchkine develops pH-activatable cytokines to treat cancer and autoimmune and inflammatory diseases.